Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Semin Hematol. 2014 May 15;51(3):177–187. doi: 10.1053/j.seminhematol.2014.05.004

Figure 4.

Figure 4

Recurrent putative driver alterations in mature B cell non-Hodgkin lymphomas. MCL -mantle cell lymphoma, FL - follicular lymphoma, BL - Burkitt’s lymphoma, DLBCL - diffuse large B cell lymphoma, SMZL - splenic marginal zone lymphoma, CLL, WM - Waldenström’s macroglobulinaemia and MM - multiple myeloma assessed by NGS (WGS - Whole Genome Sequencing, WES - Whole Exome Sequencing, TS - Targeted Sequencing [NGS or Sanger Sequencing], RNAseq, or SNP array). Shown are all alterations that were significant in CLL in at least one study. For alterations in other entities, selected ones have been validated and occurred in a significant and high proportion (>10% of cases) in at least one study, or were identified across independent studies and were significant in at least one study.